Linda Cook

Professor

University of Colorado Cancer Center
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (39)

Year:

2025

Background: The prognostic relationship between diet and endometrial cancer survival remains largely unknown. We sought to determine pre- and post-diagnosis dietary composition, glycemic load (GL), inflammatory potential (dietary inflammatory index) and quality [Canadian Healthy Eating Index (C-HEI) 2005] associations with disease-free (DFS) and overall survival (OS) among endometrial cancer survivors. In addition, we assessed associations between dietary changes with OS and explored obesity/physical activity effect modification. Methods: Survivors, diagnosed in Alberta, Canada between 2002 and 2006, completed past-year, food-frequency questionnaires at-diagnosis ( n = 503) and 3-year follow-up ( n = 395). Participants were followed to death or January 2022. Cox proportional regression estimated HR [95% confidence intervals (CI)] for dietary survival associations. Results: During 16.9 median years of follow-up, 138 participants had a DFS event and 120 died. Lower pre-diagnosis GL (HR T1vsT3 , 0.49; 95% CI, 0.25–0.97) and greater post-diagnosis energy intakes (EI) from total- and monounsaturated-fat (HR T3vsT1 , 0.48; 95% CI, 0.26–0.87) were associated with better OS. Higher pre-diagnosis C-HEI, less inflammatory diets and lower added sugar intakes were nonlinearly associated with better DFS. Consistently low pre- to post-diagnosis EI from carbohydrates and total-fats were associated with better (HR, 0.36; 95% CI, 0.18–0.72) and worse (HR, 2.26; 95% CI, 1.21–4.20) OS, respectively. Decreased pre- to post-diagnosis C-HEI was associated with worse OS. In stratified analysis, healthy diets were most beneficial for survivors with obesity and physical inactivity. Conclusions: Adherence to higher quality dietary patterns were associated with better survival. Impact: Our study provides novel evidence that both pre- and post-diagnosis diet are important prognostic factors for endometrial cancer survivors. Post-diagnosis survival associations with diet composition and quality highlight the potential for future interventions.

Year:

2025

Disease-free and overall survival outcomes for pre-diagnosis (n=503) and post-diagnosis (n=395) standard servings of major food groups in Canada's Food Guide in the Alberta Endometrial Cancer Cohort, 2002–2022

Year:

2025

We examined associations between modifiable and nonmodifiable cancer-related risk factors measured at endometrial cancer diagnosis and during early survivorship (~3 years postdiagnosis) with second primary cancer (SPC) risk among 533 endometrial cancer survivors in the Alberta Endometrial Cancer Cohort using Fine and Gray subdistribution hazard models. During a median follow-up of 16.7 years (IQR, 12.2-17.9), 89 (17%) participants developed an SPC; breast (29%), colorectal (13%), and lung (12%) cancers were the most common. Dietary glycemic load before endometrial cancer diagnosis (≥90.4 vs < 90.4 g/day: subhazard ratio [sHR] = 1.71; 95% CI, 1.09-2.69), as well as older age (≥60 vs < 60 years: sHR = 2.48; 95% CI, 1.34-4.62) and alcohol intake (≥2 drinks/week vs none: sHR = 3.81; 95% CI, 1.55-9.31) during early survivorship, were associated with increased SPC risk. Additionally, reductions in alcohol consumption from prediagnosis to early survivorship significantly reduced SPC risk (sHR = 0.34; 95% CI, 0.14-0.82). With 1 in 6 survivors developing an SPC, further investigation of SPC risk factors and targeted surveillance options for high-risk survivors could improve long-term health outcomes in this population. Reductions in dietary glycemic load and alcohol intake from prediagnosis to early survivorship showed promising risk reductions for SPCs and could be important modifiable risk factors to target among endometrial cancer survivors. This article is part of a Special Collection on Gynecological Cancer.

Year:

2024

Characterization of HGSC with co-loss of RB1 and BRCA . A, GSEA indicating up- and downregulated pathways in tumors according to BRCA and RB1 status. RB1 -alt, RB1 altered; RB1 -wt, RB1 wild-type. B, Boxplots comparing GSVA pathway enrichment scores of the cGAS-STING and Toll-like receptor signaling pathways between molecular subgroups; points represent each sample, boxes show the interquartile range (25th–75th percentiles), central lines indicate the median, and whiskers show the smallest/largest values within 1.5 times the interquartile range. Colored boxes with black points indicate the HRD and/or RB1 altered groups, whereas the gray boxes with gray points indicate the HRP and RB1 wild-type group. P values were calculated using a two-sided Mann–Whitney-Wilcoxon test. Benjamini–Hochberg adjusted P values are shown above each pairwise comparison (*, P P P ≥ 0.05). C, Bubble plot summary of HLA gene expression comparisons using DESeq2 between HGSC tumors grouped by HRD and/or RB1 status as shown. The size of the bubbles corresponds to the negative log 10 Benjamini–Hochberg adjusted P value ( P adj ) and only values with P adj ≤ 0.1 are shown. The color and intensity correspond to the log 2 fold change. Genes are grouped by their classes. D, Proportion of TILs in HGSC tumors grouped by RB1 protein expression and BRCA germline status. χ 2 P value is indicated. E, Proportion of tumors classified as each HGSC molecular subtype ( 13 ) grouped by RB1 expression and BRCA germline status. χ 2 P value is indicated. C4.DIF, C4/differentiated subtype; C2.IMM, C2/immunoreactive subtype; C1.MES, C1/mesenchymal subtype; C5.PRO, C5/proliferative subtype.

Year:

2024

Sensitivity to therapeutic agents in BRCA1 -altered cell lines with RB1 knockout. A, RB1 was knocked out using CRISPR/Cas9 in three patient-derived Australian Ovarian Cancer Study (AOCS) HGSC cell lines with either wild-type or altered BRCA1 ( BRCA1 var) background. Representative Western Blots show protein levels of RB1 and phosphorylated RB1 (pRB1) compared with GAPDH loading control in single-cell cloned, homozygous RB1 wild-type (WT) and knockout (KO) colonies in comparison with heterogeneous populations with a scramble single guide RNA (sgRNA). Independent blots were used for RB1 and pRB1. B, Cell viability was compared between RB1 WT and KO clones following treatment with cisplatin (72 h), paclitaxel (72 h), or olaparib (120 h). Nonlinear regression drug curves are shown; P values are shown in Supplementary Table S18 ( n = 3). Error bars indicate ± SEM; for some values, error bars are shorter than the symbols and thus are not visible. C, Proportion of surviving colonies following 16 days of treatment with cisplatin, paclitaxel, or a combination of both (Cis/Pac; with half of the IC50 determined per drug and cell line respectively) relative to DMF vehicle control ( n = 3 replicates). Data are presented as mean ± SEM. Mean values were compared by Student’s t test (ns, not significant; *, P P

Year:

2024

Supplementary Table S17. Half maximum inhibitory concentrations (IC50) for cisplatin (72 hours), paclitaxel (72 hours), or olaparib (120 hours) in HGSC cell lines with innate RB1 and/or BRCA1 alterations.

Year:

2024

Genomic landscape of high-grade serous ovarian tumors with co-occurring BRCA and RB1 alterations. A, Pathogenic germline and somatic alterations in HR and DNA repair genes detected by whole-genome sequencing and DNA methylation analysis of 126 primary HGSC samples ( 27 ) are shown, as well as alterations in immune genes and CCNE1 . Samples are grouped by HR and RB1 status. Bars at the top indicate the number of alterations in each listed gene per patient. Patients are annotated with survival group (LTS, long-term survivor, OS > 10 years; MTS, mid-term survivor, OS 2–10 years; STS, short-term survivor, OS 41 ) scores, and the proportion of structural variant (SV) type (DEL, deletion; DUP, duplication; INV, inversion; ITX, intra-chromosomal translocation). B, Kaplan–Meier estimates of progression-free survival (left) and overall survival (right) of patients according to HR status ( BRCA1 -type HRD; BRCA2 -type HRD; or HRP tumors) and RB1 status (altered vs. wild-type).

Year:

2024

Sensitivity to therapeutic agents in BRCA1 -altered cell lines with RB1 knockout. A, RB1 was knocked out using CRISPR/Cas9 in three patient-derived Australian Ovarian Cancer Study (AOCS) HGSC cell lines with either wild-type or altered BRCA1 ( BRCA1 var) background. Representative Western Blots show protein levels of RB1 and phosphorylated RB1 (pRB1) compared with GAPDH loading control in single-cell cloned, homozygous RB1 wild-type (WT) and knockout (KO) colonies in comparison with heterogeneous populations with a scramble single guide RNA (sgRNA). Independent blots were used for RB1 and pRB1. B, Cell viability was compared between RB1 WT and KO clones following treatment with cisplatin (72 h), paclitaxel (72 h), or olaparib (120 h). Nonlinear regression drug curves are shown; P values are shown in Supplementary Table S18 ( n = 3). Error bars indicate ± SEM; for some values, error bars are shorter than the symbols and thus are not visible. C, Proportion of surviving colonies following 16 days of treatment with cisplatin, paclitaxel, or a combination of both (Cis/Pac; with half of the IC50 determined per drug and cell line respectively) relative to DMF vehicle control ( n = 3 replicates). Data are presented as mean ± SEM. Mean values were compared by Student’s t test (ns, not significant; *, P P

Year:

2024

Expression of RB1 and survival associations across ovarian cancer histotypes. A, Representative images of IHC detection of RB1 expression in ovarian carcinoma tissues, showing examples of the three most common expression patterns: retained, lost, and subclonal loss. B, Proportion of patients with loss or retention of RB1 protein expression in tumor samples by ovarian cancer histotypes. χ 2 P value reported for difference in proportions across all histotypes. CCOC, clear cell ovarian cancer; LGSC, low-grade serous carcinoma; MOC, mucinous ovarian cancer. C, Boxplots show RB1 mRNA expression (NanoString) by RB1 protein expression status; lines indicate median and whiskers show range (Mann–Whitney test P value reported). Kaplan–Meier analysis of OS in patients diagnosed with HGSC ( D ) and ENOC ( E ) stratified by tumor RB1 expression. F, Frequency of germline BRCA wild-type (g BRCA wt) and germline BRCA pathogenic variants (g BRCA var) in patients with HGSC stratified by RB1 protein expression. χ 2 P value is reported. G, Kaplan–Meier estimates of overall survival in patients with HGSC by combined germline BRCA and tumor RB1 expression status.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Collaborators (72)

Madeleine Shackleford

Professional Research Assistant

University of Colorado Anschutz Medical Campus

UNITED STATES
View details

Junxiao Hu

Assistant Professor

University of Colorado Anschutz Medical Campus

UNITED STATES
View details

Carlo La Vecchia

Professor of Epidemiology

Università degli Studi di Torino

ITALY
View details

Elizabeth Christie

Peter MacCallum Cancer Institute

AUSTRALIA
View details

Timothy Budden

Lecturer

University of Liverpool

UNITED KINGDOM
View details

Anna E. Prizment

Faculty, Associate Professor

University of Minnesota

UNITED STATES
View details

Beth Karlan

Vice Chair

University of California, Los Angeles

UNITED STATES
View details

Xiao‐Ou Shu

Vanderbilt University Medical Center

UNITED STATES
View details

Anna Jakubowska

Head

Pomeranian Medical University

POLAND
View details

Lynne Wilkens

Professor

University of Hawaii at Manoa

UNITED STATES
View details

Sven Sandin

Associate Professor

Karolinska Institutet

SWEDEN
View details

Carlotta Sacerdote

Docenti di ruolo di Ia fascia

Università degli Studi del Piemonte Orientale Amedeo Avogadro

ITALY
View details

Anthony Swerdlow

Professor of Epidemiology

Institute of Cancer Research Sutton

UNITED KINGDOM
View details

Benjamin Bitler

Professor

University of Colorado Anschutz Medical Campus

UNITED STATES
View details

Fulvio Ricceri

University of Turin

ITALY
View details

Piet van den Brandt

Professor of Epidemiology

University of Maastricht

NETHERLANDS
View details

Martin Widschwendter

Professor; Director

University of Innsbruck

AUSTRIA
View details

P. M. Webb

Group Leader

QIMR Berghofer Medical Research Institute

AUSTRALIA
View details

Matthew Sikora

Associate Professor

University of Denver

UNITED STATES
View details

Martin Köbel

Associate Professor

University of Calgary

CANADA
View details

Shaymaa Bahnassy

Assistant Professor

Georgetown University

UNITED STATES
View details

Noah Peeri

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Rebecca B Riggins

Professor

Georgetown University

UNITED STATES
View details

Tracy O'Mara

Team Head

QIMR Berghofer Medical Research Institute

AUSTRALIA
View details

James D Brenton

University of Cambridge

UNITED KINGDOM
View details

Julie R Palmer

Boston University School of Medicine

UNITED STATES
View details

Leo Schouten

University of Maastricht

NETHERLANDS
View details

Wei Zheng

-

UNITED STATES
View details

Steffi Oesterreich

UPMC Hillman Cancer Center

UNITED STATES
View details

Cezary Cybulski

Pomeranian Medical University

POLAND
View details

Kerry S. Courneya

-

CANADA
View details

Angela Brooks-Wilson

Simon Fraser University

CANADA
View details

Tomasz Kluz

Professor

Rzeszów University

POLAND
View details

Joellen Schilkdraut

Professor

Emory University

UNITED STATES
View details

Herbert Yu

Researcher/Professor

University of Hawaii at Manoa

UNITED STATES
View details

Michael Anglesio

Associate Professor

The University of British Columbia

CANADA
View details

Ramona Erber

W2-Professorin, Oberärztin

University of Regensburg

GERMANY
View details

Usha Menon

Professor of Gynaecological Oncology

University College London

UNITED KINGDOM
View details

Sandra Orsulic

Professor

University of California, Los Angeles

UNITED STATES
View details

Cheng-Han Lee

Associate Professor

University of Alberta

CANADA
View details

Ian Campbell

Group Leader

Peter MacCallum Cancer Institute

AUSTRALIA
View details

Stacey J. Winham

Mayo Clinic College of Medicine and Science

UNITED STATES
View details

Fabio Parazzini

University of Milan

ITALY
View details

Michele L. Cote

Indiana University

UNITED STATES
View details

C Blake Gilks

-

CANADA
View details

Peter Fasching

-

GERMANY
View details

Rachael Solomon

Senior Eoidemiologist

Division of Cancer Epidemiology and Genetics, National Cancer Institute

UNITED STATES
View details

Francesmary Modugno

University of Pittsburgh

UNITED STATES
View details

Alexander Hein

-

GERMANY
View details

Jessica McNeil

Assistant Professor

University of North Carolina at Greensboro

UNITED STATES
View details

Dale Garsed

University of Melbourne

AUSTRALIA
View details

Renée Fortner

Head of Division

Deutsches Krebsforschungszentrum

GERMANY
View details

K Sundfeldt

Professor/Consultant

University of Gothenburg, Sahlgrenska Academy

SWEDEN
View details

Gregg Nelson

Gynecologic Oncologist

University of Calgary

CANADA
View details

Jo Freudenheim

SUNY Distinguished Professor and Associate Dean

University at Buffalo

UNITED STATES
View details

Jennifer Anne Doherty

Professor

University of Utah

UNITED STATES
View details

Anne Zeleniuch-Jacquotte

Professor of Population Health and Environmental Medicine

NYU School of Medicine

UNITED STATES
View details

Paul Pharoah

Professor of Cancer Epidemiology

Cedars-Sinai Medical Center

UNITED STATES
View details

Brenda Y Hernandez

University of Hawaii

UNITED STATES
View details

Eva Negri

Associate professor

University of Bologna

ITALY
View details

Michael Edwin Jones

Senior Staff Scientist

Institute of Cancer Research

UNITED KINGDOM
View details

Jan Lubiński

Head of Dept

Pomeranian Medical University

POLAND
View details

Veronica Setiawan

Associate Professor

University of Southern California

UNITED STATES
View details

Mona El-Bahrawy

Imperial College London

UNITED KINGDOM
View details

Zeynep Madak-Erdogan

Professor

University of Illinois at Urbana-Champaign

UNITED STATES
View details

Aleksandra Gentry-Maharaj

University College London

UNITED KINGDOM
View details

Susan J. Jordan

Associate Profesor

University of Queensland

AUSTRALIA
View details

Lingeng Lu

Yale School of Public Health

UNITED STATES
View details

David G. Huntsman

The University of British Columbia

CANADA
View details

Kimberly A. Bertrand

Associate Professor of Medicine

Boston University

UNITED STATES
View details

Susan Ramus

Professor of Molecular Oncology

University of New South Wales

AUSTRALIA
View details

Aline Talhouk

Assistant Professor

The University of British Columbia

CANADA
View details